文献速递淋巴瘤

小鼠ALCL样模型中存在重编程的淋巴瘤干细胞

Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model.
PubMed 文献 · Leukemia · 2020-03-17

该研究利用NPM-ALK+间变性大细胞淋巴瘤小鼠模型,发现淋巴瘤内存在异质性细胞群,其中CD4-/CD8-双阴性(DN)DN3/DN4 T细胞亚群具有淋巴瘤干细胞特性,可连续移植并分化为成熟淋巴瘤T细胞,且CD30低表达。

要点

  • 淋巴瘤干细胞存在于DN3/DN4双阴性T细胞亚群中
  • DN3/DN4淋巴瘤干细胞可连续移植并分化为成熟淋巴瘤T细胞
  • 淋巴瘤干细胞CD30低表达,可能影响抗CD30治疗长期疗效

核心结论

  • NPM-ALK驱动的CD30+小鼠淋巴瘤模型中存在淋巴瘤干细胞群,位于DN3/DN4 T细胞亚群。

研究设计与样本

  • 使用NPM-ALK+间变性大细胞淋巴瘤小鼠模型,对分选的CD4/CD8和DN淋巴瘤亚群进行连续移植实验。

主要发现

  • 已建立的NPM-ALK+淋巴瘤包含从成熟T细胞到未分化造血干细胞的异质性细胞群。
  • CD4-/CD8-双阴性淋巴瘤细胞异常表达T细胞受体α/β链。
  • 连续移植显示淋巴瘤干细胞位于DN3/DN4 T细胞群,其他亚群均不能建立连续淋巴瘤。
  • 移植的DN3/DN4淋巴瘤T细胞能够分化并产生成熟淋巴瘤T细胞。
  • 基因表达分析揭示淋巴瘤干细胞群具有干细胞样转录调控,且CD30表达水平低。

临床怎么用

  • 识别DN3/DN4淋巴瘤干细胞群可能为针对疾病起源的创新治疗策略提供靶点。
  • 淋巴瘤干细胞低CD30表达可能部分解释抗CD30靶向治疗长期效果有限。

局限性

  • 研究基于小鼠模型,结果向人类T细胞淋巴瘤的转化需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While cancer stem cells are well established in certain hematologic and solid malignancies, their existence in T cell lymphoma is unclear and the origin of disease is not fully understood. To examine the existence of lymphoma stem cells, we utilized a mouse model of anaplastic large cell lymphoma. Established NPM-ALK+ lymphomas contained heterogeneous cell populations ranging from mature T cells to undifferentiated hematopoietic stem cells. Interestingly, CD4-/CD8- double negative (DN) lymphoma cells aberrantly expressed the T cell receptor α/β chain. Serial transplantation of sorted CD4/CD8 and DN lymphoma subpopulations identified lymphoma stem cells within the DN3/DN4 T cell population, whereas all other subpopulations failed to establish serial lymphomas. Moreover, transplanted lymphoma DN3/DN4 T cells were able to differentiate and gave rise to mature lymphoma T cells. Gene expression analyses unmasked stem-cell-like transcriptional regulation of the identified lymphoma stem cell population. Furthermore, these lymphoma stem cells are characterized by low CD30 expression levels, which might contribute to limited long-term therapeutic success in patients treated with anti-CD30-targeted therapies. In summary, our results highlight the existence of a lymphoma stem cell population in a NPM-ALK-driven CD30+ mouse model, thereby giving the opportunity to test innovative treatment strategies developed to eradicate the origin of disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kreutmair S, Klingeberg C, Poggio T, et al. Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model. Leukemia. 2020. PMID: 32203142. doi:10.1038/s41375-020-0789-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。